Haploinsufficiency of the SHANK3 gene is causally linked to autism spectrum disorder (ASD), and ASD-associated genes are also enriched for chromatin remodelers. Here we found that brief treatment with romidepsin, a highly potent class I histone deacetylase (HDAC) inhibitor, alleviated social deficits in Shank3-deficient mice, which persisted for ~3 weeks. HDAC2 transcription was upregulated in these mice, and knockdown of HDAC2 in prefrontal cortex also rescued their social deficits. Nuclear localization of β-catenin, a Shank3-binding protein that regulates cell adhesion and transcription, was increased in Shank3-deficient mice, which induced HDAC2 upregulation and social deficits. At the downstream molecular level, romidepsin treatment elevated the expression and histone acetylation of Grin2a and actin-regulatory genes and restored NMDA-receptor function and actin filaments in Shank3-deficient mice. Taken together, these findings highlight an epigenetic mechanism underlying social deficits linked to Shank3 deficiency, which may suggest potential therapeutic strategies for ASD patients bearing SHANK3 mutations.
M ouse models that reflect the core symptoms of ASD, including deficits in sociability and repetitive behaviors, are crucial for preclinical investigations of pathophysiological mechanisms and novel treatment avenues 1 . Haploinsufficiency of the SHANK3 gene, which encodes a master scaffolding protein in the postsynaptic density of glutamatergic synapses 2 , is causally linked to 22q13.3 deletion syndrome (also known as Phelan-McDermid syndrome), which conveys a high risk for ASD [3] [4] [5] [6] . Deletion or loss-of-function mutations of one copy of SHANK3 account for 0.5-2.0% of ASD and intellectual disability cases 5, 6 . Human genetic studies of ASD have found that enriched mutations are located at the SHANK3 C-terminal region (exon 21) 4 , which contains binding sites for actin (and cortactin) and mGluR (and Homer) and plays a crucial role in the synaptic targeting and postsynaptic assembly of Shank3 complex.
Mouse models with Shank3 deficiency exhibit autism-associated behaviors to different extents [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Male heterozygous mice with C-terminal (exon 21) deleted Shank3 (Shank3 +/ΔC ), which exhibit reduced full-length Shank3 expression 11, 12 and loss of synaptic localization of the truncated Shank3 protein 12 , recapitulate social preference deficits and repetitive behaviors 12 . These behavioral deficits in Shank3 +/ΔC mice are attributable to the loss of NMDA-receptor (NMDAR) function and synaptic trafficking due to actin dysregulation in pyramidal neurons of prefrontal cortex (PFC) 12 , a brain region that plays an essential role in mediating social cognition 17 .
Large-scale genetic studies have revealed that many ASDassociated genes are involved in synaptic homeostasis, transcriptional regulation and chromatin-remodeling pathways [18] [19] [20] [21] . This prompted us to speculate that targeting epigenetic enzymes to normalize gene expression and ameliorate synaptic defects may be a potential strategy to relieve social deficits in ASD. Here we targeted HDAC family proteins, which generally cause silencing of gene expression via condensing the chromatin architecture. HDACs play a key role in cognitive processes 22, 23 , and altered histone acetylation and transcriptional dysfunction have been implicated in psychiatric disorders 24 ; however, the efficacy of HDAC-targeting agents in models of ASD is unknown. Here we have identified an HDAC inhibitor that persistently alleviates social deficits in Shank3-deficient mice.
Results
Treatment with the HDAC inhibitor romidepsin lastingly relieves autism-like social deficits in Shank3-deficient mice. The level of global H3 acetylation (Fig. 1a ) in the frontal cortex of Shank3 +/ΔC mice was significantly lower than that from wild-type (WT) mice. A systemic administration of low-dose romidepsin (0.25 mg/kg, intraperitoneally (i.p.), once daily for 3 d), a highly potent and brainpermeable class I-specific HDAC inhibitor (with nanomolar in vitro potency 25 ) approved by the US Food and Drug Administration (FDA) for cancer treatment [26] [27] [28] , significantly elevated the level of acetylated H3 in Shank3 +/ΔC mice, while it had little effect in WT mice. These data suggest that Shank3-deficient mice have an abnormally low level of histone acetylation, which can be restored by romidepsin treatment.
Next, we examined the impact of romidepsin on social deficits in young (5-6 weeks old) male Shank3 +/ΔC mice, which exhibit loss of social preference in the three-chamber social-interaction assay 12 . As shown in Fig. 1b,d , during the presentation of both social (Soc) and nonsocial (NS) stimuli, romidepsin (0.25 mg/kg, i.p, 3× )-treated Shank3 +/ΔC mice spent significantly more time exploring the social stimulus over the nonsocial object, similarly to WT mice, while saline-injected Shank3 +/ΔC mice showed a significant loss of the preference for the social stimulus. WT mice treated with romidepsin had unchanged social preferences. The significantly elevated social preference index in Shank3 +/ΔC mice after romidepsin treatment (Fig. 1c ) suggests that romidepsin alleviates the observed social deficits. with the HDAC inhibitor romidepsin induces robust, prolonged rescue of autism-like social deficits in Shank3-deficient mice, while a variety of drugs for psychiatric disorders fail to do so. a, Immunoblots and quantification analysis of the level of acetylated H3 and total H3 in the nuclear fraction of cortical slices from WT or Shank3 +/ΔC (Het) mice injected (i.p.) with saline (sal) or romidepsin (RMD, 0.25 mg/kg, 3× ). Immunoblotting was performed 4-5 d postinjection (F 1,20 = 11.3, P = 0.0031; *P < 0.05, two-way ANOVA, n = 6 mice per group). b,c, Plots showing the time spent investigating either the social (Soc) or nonsocial (NS) stimulus (b) and the social preference index (c) during three-chamber sociability testing of salineinjected WT (n = 18), saline-injected Shank3 +/ΔC (n = 17), RMD-treated Shank3 +/ΔC (n = 17) and RMD-treated WT (n = 12) mice (b: F 3,120 = 11.4, P < 0.0001; +++ P < 0.001, Soc vs. NS, **P < 0.01, ***P < 0.001, two-way ANOVA; c: F 1,60 = 58.5, P < 0.0001; ***P < 0.001, two-way ANOVA). d, Representative heat maps illustrating the time spent by all groups in different locations of the three chambers from the social preference tests. Soc and NS stimuli are labeled with the circles. e, Plots of social preference index in Shank3 +/ΔC mice treated with RMD (n = 10) or saline (n = 10) at different timepoints (F 1,18(treatment) = 124.3, P < 0.0001; *** P < 0.001, saline vs. RMD; ### P < 0.001, preinjection vs. postinjection, two-way repeated-measures ANOVA). f, Plots of social preference index in Shank3 +/ΔC mice treated with different doses of RMD (0.025 mg/kg, n = 9; 1 mg/kg, n = 8) at different timepoints (F 1,15(treatment) = 51.3, P < 0.0001; *** P < 0.001, 1 mg/kg vs. 0.025 mg/kg RMD; ### P < 0.001, preinjection vs. postinjection, two-way repeated-measures ANOVA). g, Scatter plots showing total sniffing time in social-approach tests of saline-injected WT (n = 12), saline-injected Shank3 +/ΔC (n = 14), RMD-treated Shank3 +/ΔC (n = 12) and RMDtreated WT (n = 12) mice (F 1,46 = 6.0, P = 0.018; *P < 0.05, **P < 0.01, two-way ANOVA). h, Representative heat maps illustrating time spent in different locations of the apparatus from social approach tests of all groups. Locations of social stimuli are labeled with circles. i-n, Plots of social preference index in Shank3 +/ΔC mice treated with (i) fluoxetine (10 mg/kg, i.p., 14× , n = 9), (j) clozapine (5 mg/kg, i.p., 3× , n = 11), (k) valproic acid (VPA, 100 mg/kg, i.p., 3× , n = 11), (l) aripiprazole (1 mg/kg, i.p., 3× , n = 9), (m) risperidone (0.1 mg/kg, i.p., 3× , n = 10) or (n) trichostatin A (TSA, 0.5 mg/kg, i.p., 3× , n = 8; F 2,30 = 19.2 (VPA), P < 0.0001; F 2,21 = 19.7, P < 0.0001 (TSA); ### P < 0.001 (preinjection vs. postinjection), one-way ANOVA.) o, Representative heat maps illustrating the time spent in different locations of the three chambers from the social preference tests of a Shank3 e4-9 mouse before and after RMD treatment (0.25 mg/kg, i.p., 3× ). p, Box plots showing the time spent investigating either Soc or NS stimulus during sociability testing in WT (n = 8) or homozygous Shank3 e4-9 mice (n = 10) before and after RMD treatment (F 2,50 = 9.2, P = 0.0003; +++ P < 0.001, Soc vs. NS; *P < 0.05, ***P < 0.001, two-way ANOVA). q, Scatter plots showing the preference index of the sociability testing in individual Shank3 e4-9 mice before and after RMD treatment (n = 10; t 9 = 4.36, **P = 0.0018, paired two-tailed t test). r, Plots of social preference index in Shank3 e4-9 mice (n = 10) treated with RMD at different timepoints (F 6,63 = 11.8, P < 0.0001; *P < 0.05, **P < 0.01, ***P < 0.001, preinjection vs. postinjection, one-way ANOVA). Shank3 +/ΔC mice (a-n) and WT mice (a-n,p) are all males, 5-6 weeks old; Shank3 e4-9 mice (o-r) are 6 males and 4 females, 5-6 weeks old. Data are presented as median with interquartile ranges (a,b,p) or mean ± s.e.m. (c,e-g,i-n,q,r). Each set of the experiments was replicated at least three times. See Supplementary Fig. 8 for blot source data.
We then examined how long the effect of a brief romidepsin treatment could last. Social preference assays were performed in Shank3 +/ΔC mice before and at various timepoints after drug treatment. As shown in Fig. 1e , the significantly increased social preference index in Shank3 +/ΔC mice persisted for at least 21 d postinjection of romidepsin, while no improvement in social preference was found with repeated measurements of saline-injected Shank3 +/ΔC mice. Romidepsin treatment not only persistently improved social preference, but also induced a sustained increase in the time spent interacting with the social stimulus in young Shank3 +/ΔC mice ( Supplementary Fig. 1a,b) . The prolonged effect of romidepsin is consistent with the long duration of human response to romidepsin (13.7 months) revealed by pharmacokinetics analyses 26, 27 . Romidepsin treatment of adult Shank3 +/ΔC mice gave a less potent and more transient effect on social behaviors ( Supplementary Fig. 1c,d ), suggesting that the therapeutic efficacy of the drug is influenced by developmental processes.
The effective dose of romidepsin in rescuing social deficits (0.25 mg/kg, i.e., 0.75 mg/m 2 , i.p., once daily for 3 d) is equivalent to ~5% of the clinical anticancer dose in humans (14 mg/m 2 , intravenously, once a week for 3 weeks). Dose-response studies ( Fig. 1f ) indicated that a higher dose of romidepsin (1 mg/kg, i.p., 3× ) had similar long-lasting rescuing effects on the social preference behavior in Shank3 +/ΔC mice, while a lower dose (0.025 mg/kg, i.p., 3× ) was ineffective in improving the social deficits persistently. Thus, 0.25 mg/kg romidepsin was used in the following studies.
We further examined the impact of romidepsin on social approach behaviors in young Shank3 +/ΔC mice. As shown in Fig.  1g ,h, compared to WT mice, Shank3 +/ΔC mice spent significantly less time approaching and interacting with social stimuli, which was almost completely reversed by romidepsin treatment. Taken together, these results suggest that brief treatment with low-dose romidepsin can lead to prolonged rescue of autism-like social deficits in the Shank3-deficient model.
Moreover, we examined whether other pharmacological agents currently used for various psychiatric disorders were able to rescue autism-like social deficits in Shank3 +/ΔC mice. As shown in Fig. 1i , treatment with the selective serotonin reuptake inhibitor (SSRI) antidepressant fluoxetine (once daily for 14 d) failed to induce any improvement in social preference in the three-chamber socialinteraction assay. The atypical antipsychotics clozapine (once daily for 3 d) was also ineffective in rescuing social deficits (Fig. 1j ). The mood stabilizer valproic acid (once daily for 3 d), a low-affinity class I HDAC inhibitor (with millimolar in vitro potency 25 ), only transiently increased the social preference index, but this effect disappeared within a few days after the end of treatment ( Fig. 1k ). No improvement in social preference was observed with aripiprazole (once daily for 3 d; Fig. 1l ) or risperidone (once daily for 3 d; Fig. 1m ), the only drugs approved by FDA for ASD treatment, which is consistent with the lack of effect of these drugs on the social communication deficits observed in ASD patients despite their utility in managing irritability and repetitive behaviors 29 . All these antipsychotics failed to increase the time spent interacting with the social stimulus in Shank3 +/ΔC mice ( Supplementary Fig. 2a-e ). Treatment with the pan-HDAC inhibitor trichostatin A (once daily for 3 d) significantly but transiently increased social preference index ( Fig. 1n ) and social interaction time ( Supplementary Fig. 2f ,g) in Shank3 +/ΔC mice. These data suggest that the potent and prolonged effectiveness of romidepsin in alleviating social deficits is unique.
To examine the generalizability of the rescue effect of romidepsin on social deficits, we examined another Shank3-deficient model, Shank3 e4-9 mice, which exhibit the loss of major Shank3 isoforms because of the deletion of N-terminal exons 4-9 (ref. 10 ). As shown in Fig. 1o -q, in the three-chamber sociability test, homozygous Shank3 e4-9 mice had significantly impaired social preference, consistent with previous findings 10 . After romidepsin treatment (0.25 mg/kg, i.p, 3× ), the social interaction time and social preference index were significantly elevated. Moreover, the rescue effect of romidepsin in Shank3 e4-9 mice was sustained for ~3 weeks (Fig. 1r) , similarly to what was found in Shank3 +/ΔC mice. These results suggest that romidepsin is generally efficacious in mouse models of Shank3 deficiency.
A variety of other behaviors were also examined in romidepsin-treated young Shank3 +/ΔC mice. Compared to WT mice or saline-injected Shank3 +/ΔC mice, no differences were observed with romidepsin treatment in locomotion tests ( Fig. 2a ). Rotarod tests also found no difference with romidepsin treatment (Fig. 2b) . Romidepsin-or saline-treated Shank3 +/ΔC mice spent similar amounts of time in the center in open-field tests, compared to WT mice (Fig. 2c ). These data suggest that romidepsin does not alter motor coordination or anxiety-like behavior. Romidepsin failed to normalize the increased repetitive grooming in Shank3 +/ΔC mice ( Fig. 2d ).
Romidepsin treatment did not cause nonspecific behavioral effects, suggesting that it is generally safe, consistent with comprehensive safety studies showing that this FDA-approved anticancer drug is safe and well-tolerated 26, 28 . To further examine the potential neuronal toxicity of low-dose romidepsin treatment in young Shank3 +/ΔC mice, we performed immunocytochemical experiments to compare neural survival rates. Pyramidal neurons were immunostained with CaMKII and NeuN, and cell density was counted in the PFC region. As shown in Fig. 2e ,f, neuronal morphology and density were not altered by romidepsin treatment.
HDAC2 is upregulated in Shank3-deficient mice via a β-cateninmediated transcriptional mechanism. To find out which HDAC family member may mediate the therapeutic effect of romidepsin, we first examined the expression of class I HDACs. Quantitative PCR analyses indicated that the level of HDAC2 mRNA was significantly higher in PFC lysates from Shank3 +/ΔC mice, while the level of HDAC1, HDAC3 and HDAC8 mRNA was largely unchanged ( Fig. 3a ). Western blot analyses showed that the protein level of HDAC2, but not HDAC1, in the nucleus fraction of PFC was significantly higher in Shank3 +/ΔC mice (Fig. 3b ). Significantly elevated HDAC2 mRNA and HDAC2 protein were also detected in the PFC of Shank3 e4-9 mice (Fig. 3c ). This suggests that upregulated HDAC2 may be responsible for the abnormally low histone acetylation in Shank3-deficient mice.
Next, we tested whether knockdown of HDAC2 by a stereotaxic injection of HDAC2 short hairpin RNA (shRNA) lentivirus to medial PFC of Shank3 +/ΔC mice might rescue the social deficits. To prevent potential off-target effects, two shRNA lentiviruses targeting different sequences of the mouse HDAC2 gene (HDAC2 shRNA-1 and HDAC2 shRNA-2) were used. As shown in Fig. 3d , compared to a scrambled control shRNA, HDAC2 shRNA-1 specifically knocked down the mRNA level of HDAC2, but not other class I HDAC family members. HDAC2 shRNA-2 was also highly effective in suppressing HDAC2 mRNA. The level of HDAC2 protein was significantly diminished by injecting these HDAC2 shRNA lentiviruses in vivo. Behavioral assays indicated that Shank3 +/ΔC mice with PFC injection of either HDAC2 shRNA-1 or HDAC2 shRNA-2 lentivirus exhibited significantly increased social interaction times and improved preferences for social stimuli over nonsocial objects in three-chamber sociability tests ( Fig. 3e-g) . These data suggest that knockdown of HDAC2 in PFC induces a similar rescuing effect as romidepsin treatment on social deficits.
To understand how the loss of Shank3 at synapses leads to the upregulation of HDAC2 transcription in the nucleus, we turned our attention to β -catenin, a nucleocytoplasmic shuttle protein involved in both cell adhesion and transcriptional regulation 30 . In the default state, β -catenin is phosphorylated and retained in the cytoplasm, where it is constitutively targeted for proteasomal degradation.
Activation of Wnt signaling results in the nuclear translocation of β -catenin, where it activates target genes in a complex with LEF-TCF transcription factors. Neural activity induces the redistribution of β -catenin into spines, where it interacts with the adhesion molecule cadherin to influence synaptic size and strength 31 . β -catenin has also been identified as a critical mediator of dendritic morphogenesis via interacting with cadherin to stabilize actin cytoskeleton 32 . Our coimmunoprecipitation experiments revealed that β -catenin bound to Shank3 in WT mice (Fig. 4a ). In PFC of Shank3 +/ΔC mice, β -catenin at the synaptic membrane fraction was significantly reduced, while the level of active (nonphosphorylated) β -catenin in the cytosol and the level of β -catenin in the nucleus were significantly elevated ( Fig. 4b ).
Decreased synaptic β -catenin and increased nuclear β -catenin were also observed in PFC of Shank3 e4-9 mice (Fig. 4c ). These results suggest that Shank3 deficiency induces the redistribution of β -catenin from synapses to nucleus, probably due to the attenuated association of β -catenin with synaptic scaffolding proteins and adhesion molecules.
The increased nuclear translocation of β -catenin in Shank3deficient mice suggests that it can activate the TCF-LEF transcriptional machinery to regulate target genes. Our chromatin immunoprecipitation (ChIP) assays indicated that β -catenin specifically associated with the HDAC2 promoter region containing TCF-LEF binding elements ( Fig. 4d ). β -catenin enrichment on the HDAC2 promoter was significantly increased in PFC of Shank3 +/ΔC mice (Fig. 4e ), implicating β -catenin in the upregulated transcription of HDAC2. Other β -catenin target genes found in cancer cells or neural stem cells, such as Vegf, Jun (encoding c-Jun), Ccnd1 (encoding Cyclin D1) and Neurod1, were not significantly altered in PFC of Shank3 +/ΔC mice ( Fig. 4f ).
To further reveal the involvement of β -catenin in the regulation of genes and behaviors, we elevated β -catenin expression by injecting β -catenin-expressing adenovirus into the PFC of WT mice. A high level of β -catenin was found in the nucleus of PFC pyramidal neurons ( Fig. 4g ). HDAC2 mRNA was significantly and specifically upregulated by β -catenin overexpression in PFC of WT mice ( Fig. 4h) , similarly to what was found in Shank3 +/ΔC mice. Moreover, social preference deficits were induced in WT mice with elevated β -catenin expression in PFC ( Fig. 4i-k) , reminiscent of the behavioral consequence of upregulated nuclear β -catenin in Shank3-deficient mice.
Next, we diminished β -catenin expression by injecting β -catenin shRNA lentivirus into the PFC of Shank3-deficient mice. Effective knockdown of β -catenin expression in vivo was achieved with β -catenin shRNA (Fig. 4l ). HDAC2 expression in PFC was significantly reduced in β -catenin shRNA-injected Shank3 +/ΔC mice, compared to those injected with a scrambled control shRNA ( Fig. 4m ). Furthermore, Shank3 +/ΔC mice with β -catenin knockdown in PFC exhibited significantly increased social interaction times and social preference in three-chamber sociability tests ( Fig. 4n-p) . Taken together, these results provide direct evidence of the sufficiency and necessity of β -catenin in the regulation of HDAC2 and social behavior. Romidepsin treatment elevates NMDAR transcription and restores NMDAR function in Shank3-deficient mice. We then sought to determine molecular mechanisms downstream of HDAC inhibition that may underlie the amelioration of social deficits.
Diminished synaptic signals at glutamatergic synapses are strongly linked to autism-like phenotypes, including social deficits and repetitive behaviors [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] , making glutamate receptors a potential key target of romidepsin. Quantitative PCR analyses ( Fig. 5a ) indicated Tubulin 0 s~20 s 0 s~20 s 0 s~20 s 0 s~20 s Supplementary Fig. 8 for blot source data. Supplementary Fig. 9 for blot source data.
that in Shank3 +/ΔC mice treated with romidepsin, the mRNA level of Grin2a (encoding the NMDAR NR2A subunit) was significantly elevated, while the transcripts encoding other NMDAR subunits (Grin1, Grin2b) or AMPA-receptor subunits (Gria1, Gria2) were not significantly changed. Consistently, romidepsin significantly increased the expression of the NR2A subunit, but not other glutamate receptor subunits. The reduced Shank3 mRNA and protein levels in Shank3 +/ΔC mice were not restored by romidepsin treatment (Fig. 5b,c) .
The transcriptional increase of Grin2a by romidepsin prompted us to investigate whether histone acetylation of NMDA receptors was altered by this HDAC inhibitor. To test this, we performed ChIP assays to examine the histone acetylation at Grin2a and Grin2b promoters in PFC neurons. H3 acetylation ( Supplementary Fig. 3 ) was identified at the Grin2a proximal promoter region (~200 bp from transcription start site or TSS) and Grin2b promoter region (~700 bp from TSS). As shown in Fig. 5d , romidepsin treatment significantly increased H3 acetylation at the Grin2a promoter in Supplementary Fig. 9 for blot source data.
Shank3 +/ΔC mice. No significant effect of romidepsin on H3 acetylation at Grin2b promoter was observed. These data suggest that romidepsin treatment of Shank3 +/ΔC mice elevates Grin2a gene expression by enhancing its histone acetylation. The upregulation of Grin2a transcription by romidepsin could lead to elevated NMDAR function in Shank3 +/ΔC mice. Thus, we performed electrophysiological experiments to record NMDARmediated excitatory postsynaptic currents (EPSC) 3-5 d after romidepsin treatment in layer V PFC pyramidal neurons, which exhibit the clearest deficits in the brains of children with autism 33 . As shown in Fig. 5e , the amplitudes of NMDAR-EPSC induced by a series of stimulus intensities were markedly reduced in salineinjected Shank3 +/ΔC mice, compared to saline-injected WT mice. A strong recovery of the input-output curves of NMDAR-EPSC was observed in PFC neurons of Shank3 +/ΔC mice with romidepsin treatment. AMPA-receptor (AMPAR)-ESPC were unchanged in Shank3 +/ΔC mice treated with romidepsin or saline (Fig. 5f) . The NMDAR-to AMPAR-EPSC ratio was significantly reduced in Shank3 +/ΔC mice and was also restored by romidepsin treatment (Fig. 5g) . In contrast, fluoxetine treatment (10 mg/kg, i.p. 14× ) failed to elevate NMDAR-EPSC in Shank3 +/ΔC mice (Fig. 5h) . Moreover, in PFC pyramidal neurons of HDAC2 shRNA-injected Shank3 +/ΔC mice, diminished NMDAR were significantly restored (Fig. 5i) . The romidepsin-induced rescue of NMDAR-EPSC, as well as the romidepsin-induced normalization of global H3 acetylation, could be observed 16-18 d post-treatment, but not 30-32 d posttreatment ( Supplementary Fig. 4 ), consistent with the therapeutic time window of romidepsin on behaviors (Fig. 1e) . These results suggest that the recovery of NMDAR function in PFC may underlie the rescue of social deficits in Shank3-deficient mice with HDAC2 inhibition or knockdown.
Romidepsin treatment elevates the transcription of actin regulators and restores F-actin in Shank3-deficient mice. To determine the potential existence of other molecular targets of romidepsin, we focused on various actin regulators in the 'Shank3 interactome' 34 that could regulate synaptic structure and NMDAR trafficking 12 .
Enriched mutations in genes regulating actin filament networks have been identified in genetic analyses of ASD patients 19, 35 , suggesting that actin dysregulation at glutamatergic synapses is a potential pathophysiological mechanism. It has been found that the Rac1-LIMK-PAK-cofilin signaling pathway is disrupted in Shank3-deficient mice, leading to F-actin dysregulation 12 , so we first examined the mRNA levels of these genes. As shown in Fig. 6a , Arhgef7, which encodes β PIX, the guanine nucleotide exchange factor for Rac1 and a Shank-interacting protein at excitatory synaptic sites 36 , was significantly lost in Shank3 +/ΔC mice, and romidepsin treatment rescued Arhgef7 gene transcription. The significantly decreased Limk1, which encodes a major Rac1 downstream target controlling cofilin activity, was also restored by romidepsin treatment of Shank3-deficient mice. The mRNA levels of Rac1, Pak1/2/3 and Cfl1 (encoding cofilin) were largely unchanged.
The mRNA levels of several other Shank3-interacting actin regulators that have been identified as ASD risk factors 19 were also examined. As shown in Fig. 6b, Cttnbp2 , which encodes a protein binding to cortactin (an F-actin-and Shank3-interacting protein), was upregulated in Shank3 +/ΔC mice treated with romidepsin. A similar upregulation was found in Ank2 (encoding Ankyrin2), while Cttn (encoding cortactin) and Syngap1 mRNAs showed no change.
We further examined the alteration of protein levels of these actin regulators. As shown in Fig. 6c , the diminished expression of β PIX and LIMK1 in Shank3-deficient mice was restored by romidepsin treatment. Moreover, romidepsin significantly increased the protein level of CTTNBP2 and Ank2 without altering cortactin or SYNGAP.
To test whether the transcriptional increase of actin regulators by romidepsin could be due to increased histone acetylation, we performed ChIP assays to examine the histone acetylation at Arhgef7 and Limk1 promoters in PFC neurons. H3 acetylation ( Supplementary Fig. 5 ) was identified at the Arhgef7 promoter region (~800 bp from TSS) and Limk1 promoter region (~500 bp from TSS). As shown in Fig. 6d , romidepsin treatment of Shank3 +/ ΔC mice significantly increased the enrichment of H3 acetylation at Arhgef7 promoter and Limk1 promoter.
Romidepsin-induced upregulation of key actin regulators in the Shank3 interactome may help to restore and maintain the integrity of actin cytoskeleton at synapses. To test this, we performed immunostaining with phalloidin to directly visualize F-actin. As shown in Fig. 6e,f and Supplementary Fig. 6 , compared to WT mice, Shank3 +/ΔC mice (saline-injected) had a significant decrease of F-actin expression in PFC slices, and romidepsin treatment restored cortical actin filaments to the normal level. Expression of PSD-95 in PFC of Shank3 +/ΔC mice was unchanged by romidepsin treatment. The normalization of actin filaments may facilitate actin-based NMDAR membrane delivery.
To examine the region-specificity of romidepsin-induced gene expression changes, we performed qPCR profiling in several other brain regions and peripheral organs. In contrast to what was found in PFC, the levels of mRNA encoding NMDAR subunits (Grin1, Grin2a and Grin2b) and actin regulators (Arhgef7 and Limk1) in dorsal striatum, ventral tegmental area, kidney and heart of Shank3 +/ΔC mice were not significantly altered by romidepsin treatment ( Supplementary Fig. 7 ).
Romidepsin treatment induces genome-wide restoration or elevation of expression of genes involved in neural signaling
in PFC of Shank3-deficient mice. Finally, to determine whether HDAC inhibition has genome-wide effects on gene expression, we used RNA sequencing to analyze the mRNA profile in PFC of WT and Shank3 +/ΔC mice treated with romidepsin or saline control. We mapped the sequences to 24,420 mouse genes. Compared to WT mice, in saline-treated Shank3 +/ΔC mice 365 genes showed a change in expression values of at least 1.2-fold and P ≤ 0.01 (213 downregulated, 152 upregulated). In romidepsin-treated Shank3 +/ΔC mice, many of the downregulated genes (n = 187 genes) were normalized to control values (Supplementary Table 1 ). The heat map generated with the expression values for the 187 restored genes showed that the saline-treated Shank3 +/ΔC samples clustered together and separated from the WT samples. Moreover, romidepsin-treated Shank3 +/ΔC samples were closer to those from WT than to the saline-treated Shank3 +/ΔC samples (Fig. 7a ). Further analysis of the romidepsinrestored genes revealed enrichment in actin cytoskeleton-mediated transport, signal transduction pathways and developmental processes (Fig. 7b ). In addition, romidepsin treatment increased the expression of 41 genes that were unchanged in Shank3 +/ΔC samples (Supplementary Table 2 ), which were enriched in cell-cell signaling, synaptic transmission and neurotransmitter secretion (Fig. 7c) . These results suggest that romidepsin treatment can rescue or elevate the expression of many genes involved in neural signaling in Shank3-deficient mice, which may collectively contribute to its therapeutic effects on behavioral deficits (Fig. 7d ).
Discussion
Here we show that Shank3-deficient mice exhibit an abnormally low level of histone acetylation resulting from HDAC2 upregulation in the PFC. Brief treatment with a low dose of romidepsin, a potent class I HDAC inhibitor, leads to robust and long-lasting rescue of social deficits, a core symptom of ASD. This effect of romidepsin was unique, as many of the pharmacological agents currently used in psychiatric practice, including fluoxetine, clozapine, valproic acid, risperidone and aripiprazole, all fail to profoundly and persistently improve social behaviors in the Shank3 model. This low-dose romidepsin treatment does not induce locomotor deficits, changes in anxiety-like behavior or neuronal loss in young animals. The most effective therapeutic window of romidepsin is the juvenile to late-adolescent period, which is a critical developmental stage for social and communication skills. The sustained rescue effect on social deficits of a single-round administration of romidepsin in young Shank3-deficient mice is promising, but it is limited by the lack of chronic effects in adulthood with repeated administrations. Using romidepsin as a tool compound to interrogate the biology of Shank3 deficiency, we demonstrated how aberrations in synaptic, transcriptional and epigenetic pathways, all of which have been implicated in autism [19] [20] [21] , are interconnected.
One critical question is the molecular mechanism underlying the epigenetic aberrations in Shank3 deficiency models. We found that Shank3 deficiency induced nuclear translocation of its binding partner at synapses, β -catenin. HDAC2 transcription is upregulated in Shank3-deficient mice, which is associated with the increased enrichment of β -catenin at the HDAC2 promoter region containing TCF-LEF binding elements. Direct overexpression of β -catenin in PFC of WT mice leads to the upregulation of HDAC2 transcription, and knockdown of β -catenin in PFC of Shank3-deficient mice leads to the reduction of HDAC2 transcription, further suggesting that HDAC2 is a target gene of β -catenin. Moreover, social deficits are rescued by inhibition of HDAC2, knockdown of HDAC2 or knockdown of β -catenin in PFC of Shank3-deficient mice, and they are induced by elevating β -catenin expression in PFC of WT mice. These bidirectional lines of evidence strongly suggest that β -catenin-HDAC2 plays a causal role in social deficits of Shank3deficiency models and the therapeutic effect of romidepsin.
Finding potential targets downstream of HDAC inhibition involved in the amelioration of social deficits is another challenge. Aberrant synaptic function resulting from genetic mutations is thought to be a major pathogenic factor in ASD [18] [19] [20] 37, 38 . The behavioral abnormalities exhibited in Shank3-deficient mice have been attributed to the alteration of glutamatergic synapses [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . In particular, aberrations in NMDARs, a Shank3-associated key synaptic protein 2 controlling neural development and synaptic plasticity underlying cognitive processes, are strongly linked to social deficits 12, [39] [40] [41] . Previous studies demonstrate that the Shank3-deficiency-induced NMDAR hypofunction is due to the loss of actin-based synaptic delivery of NMDARs because of the reduced Rac1-PAK-cofilin signaling 12, 42 . Romidepsin treatment of Shank3-deficient mice normalizes the aberrant histone acetylation and elevates the transcription of many downstream target genes, including NMDAR subunits and key actin regulators, leading to the restoration of synaptic NMDAR function and F-actin in PFC neurons. These results are also supported by our RNA sequencing data. The majority of the 213 downregulated genes in Shank3-deficient mice was restored by romidepsin treatment, and these genes are highly enriched in actin cytoskeleton-mediated transport, signal transduction pathways and developmental processes. The reversal of the haploinsufficiency of a number of genes identified as key ASD risk factors provides a potential mechanism for the romidepsin-induced rescue of social deficits in Shank3-deficient mouse models.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41593-018-0110-8. . An upright plastic drinking cup was placed on top of each capsule to prevent the subject mouse from climbing on top. The first phase contained two identical nonsocial stimuli (folded black papers); the second phase contained a nonsocial (NS) stimulus (a wood block) and a social (Soc) stimulus (age-and sex-matched mouse of the same strain). Locations of the NS and Soc stimuli were counterbalanced. Animals were habituated to the three-chamber apparatus 1 d before the initial testing. During habituation, two empty capsules were placed in the side chambers, and animals were allowed to explore for 10 min. During the sociability measurement, different stimuli were placed in the capsules in the side chambers, and the test animal was placed in the center chamber and was free to explore the apparatus for 10 min in each phase. The subject mouse was returned to its home cage during the 5-min intervals between test phases. The chamber was cleaned with 75% ethanol after each phase. Interaction time was counted based on 'investigating' behaviors of the test animal toward each stimulus. In earlier experiments, an experimenter measured the time the test animal spent actively seeking and sniffing the stimulus. In later experiments, a computer running ANY-maze behavior tracking software (Stoelting, Wood Dale, IL) measured the time the test animal spent in close proximity to the capsule (distance of animal head to cup edge: ≤ 3.5 cm). Data generated manually and automatically were consistent, so they were pooled together. Preference scores were calculated, where time spent with one stimulus was subtracted from the time spent with the other stimulus and divided by the total time spent exploring both stimuli. , where Δ C T = C T(target) -C T(Gapdh) , and Δ (Δ C T ) = Δ C T(treated group) -Δ C T(WT + saline) . C T (threshold cycle) is defined as the fractional cycle number at which the fluorescence reaches 10 × the s.d. of the baseline. A total reaction mixture of 25 μ L was amplified in a 96-well thin-wall PCR plate (Bio-Rad) using the following PCR cycling parameters: 95 °C for 5 min followed by 40 cycles of 95 °C for 30 s, 55 °C for 30 s and 72 °C for 60 s. Primers for all target genes are listed in Supplementary Table 3 .
Immunohistochemistry. Mice were anesthetized and transcardially perfused with PBS, followed by 4% paraformaldehyde (PFA) before brain removal. Brains were postfixed in 4% PFA for 2 d and cut into 100-μ m slices. Slices were cut coronally and permeabilized using 0.5% Triton in PBS for 1 h, washed and blocked for 1 h in PBS containing 3% BSA and 0.3% Triton. After washing, slices were incubated with the primary antibody against CaMKII (1:500, Santa Cruz Biotechnology, sc-9035), NeuN (1:1,000, Millipore, MAB377) or PSD-95 (Neuromab, 75-028, 1:1,000) for 48 h at 4 °C. After washing three times (0.5 h, 1 h and 1 h with gentle shaking) in PBS, slices were incubated with one or two secondary antibodies (Alexa Fluor 488, Invitrogen, A21202, 1:1,000; or Alexa Fluor 594, Invitrogen A11032) for 1 h at room temperature, followed by three washes with PBS. For F-actin staining, slices were then incubated with DAPI antibody (1:10,000) for 10 min at room temperature, followed by three washes with PBS. Slices were mounted on slides with Vectashield mounting media (Vector Laboratories). Images were acquired using a 40 × objective on a Zeiss LSM 510 confocal microscope. All specimens were imaged under identical conditions and analyzed with identical parameters using Image J software. Z-axis stacked confocal images (10) of 9 PFC areas (225 μ m × 225 μ m) from 3-4 slices per animal were quantified.
Electrophysiological recordings.
Whole-cell voltage-clamp recording was used to measure synaptic currents in layer V pyramidal neurons of PFC slices, as previously described 12, 43 . Mouse brain slices (300 µ m) were positioned in a perfusion chamber attached to the fixed stage of an upright microscope (Olympus) and submerged in continuously flowing oxygenated ACSF (in mM: 130 NaCl, 26 NaHCO 3 , 1 CaCl 2 , 5 MgCl 2 , 3 KCl, 1.25 NaH 2 PO 4 , 10 glucose, pH 7.4, 300 mOsm). Bicuculline (20 µ M) and CNQX (20 µ M) were added in NMDAR-EPSC recordings. Bicuculline and d-APV (50 μ M) were added in AMPAR-EPSC recordings. Patch electrodes contained the following internal solution (in mM): 130 cesium-methanesulfonate, 10 CsCl, 4 NaCl, 10 HEPES, 1 MgCl 2 , 5 EGTA, 2 QX-314, 12 phosphocreatine, 5 MgATP, 0.2 Na 3 GTP, 0.1 leupeptin, pH 7.2-7.3, 265-270 mOsm. Layer V mPFC pyramidal neurons were visualized with a 40 × water-immersion lens and recorded with the Multiclamp 700 A amplifier (Molecular Devices, Sunnyvale, CA). Evoked synaptic currents were generated with a pulse from a stimulation isolation unit controlled by an S48 pulse generator (Grass Technologies, West Warwick, RI). A bipolar stimulating electrode (FHC, Bowdoinham, ME) was placed ~100 μ m from the neuron under recording. For NMDAR-EPSC, the cell (clamped at -70 mV) was depolarized to + 40 mV for 3 s before stimulation to fully relieve the voltage-dependent Mg 2+ block. Membrane potential was maintained at -70 mV for AMPAR-EPSC recordings.
For input-output responses, synaptic currents were elicited by a series of pulses with varying stimulation intensities (50-90 µ A) delivered at 0.05 Hz. To obtain the NMDAR-to AMPAR-EPSC ratio, AMPAR-EPSC were first recorded at -70 mV in ACSF solution (containing bicuculline). Then the mixture of AMPAR-EPSC and NMDAR-EPSC was recorded at + 40 mV with the same stimulation pulse (0.4 ms, 70 μ A). The peak of NMDAR-EPSC was calculated at 40 ms from the onset of the EPSC mixture.
Virus generation and delivery. The shRNA oligonucleotide targeting mouse HDAC2 sequence (CCCAATGAGTTGCCATATAAT, Open Biosystem) was inserted in the lentiviral vector pLKO.3 G (Addgene), which contains an eGFP marker. For the production of lentiviral particles, a mixture containing the pLKO.3 G shRNA plasmid (against HDAC2), psPAX2 packaging plasmid and pMD2.G envelope plasmid (Addgene) was transfected to HEK-293FT cells using Lipofectamine 2000. The transfection reagent was removed 12-15 h later, and cells were incubated in fresh DMEM (containing 10% FBS + penicillin/ streptomycin) for 24 h. The media harvested from the cells, which contained lentiviral particles, was concentrated by centrifugation (2,000 g, 20 min) with Amicon Ultra Centrifugal Filter (Ultracel-100K, Millipore). The concentrated virus was stored at -80 °C. Another shRNA lentivirus targeting different sequences of the mouse HDAC2 gene (CATGAGAGATGGTATAGAT, GCTTGGTTGTTTCAATCTA, ACATGCACCTGGTGTTCAA) was obtained from Santa Cruz Biotech (sc-29346-V). The GFP-tagged β -catenin adenovirus was obtained from Vector Biolabs (1182). The shRNA lentivirus targeting mouse beta-catenin gene (GCCTTCAGATCTTAGCTTA, CAGCTGGAATTCTCTCTAA, CTGCAGAACTCCAGAAAGA, GTCGAGGAGTAACAATACA) was obtained from Santa Cruz Biotech (sc-29210-V). In vivo delivery of the viral suspension (1 µ L each side) was achieved by stereotaxic injection bilaterally into medial PFC (2.0 mm anterior to bregma; 0.25 mm lateral) with a Hamilton syringe (needle gauge 31, extended to a depth of 2.0 mm below the tissue surface) as previously described 12, 44 .
RNA sequencing and bioinformatic analysis. PFC samples were obtained from three WT mice, three saline-treated Shank3 +/ΔC mice and two romidepsin-treated Shank3 +/ΔC mice. We generated strand-specific RNA libraries from 1 μ g purified RNA using TruSeq Stranded Total RNA Plus Ribo-zero kits (Illumina). Sequencing was performed at the Genomics and Bioinformatics Core of the State University of New York at Buffalo. Single-end reads per sample were obtained using the HiSeq 2500 platform from Illumina. Reads were first trimmed using Cutadapt 45 to remove the 3′ end adapters and trailing sequences, followed by aligning to mouse RefSeq mRNAs using TopHat2 46 . Transcript counts were estimated using HTSeq 47 . Differences in gene expression levels between samples were assessed with edgeR 48 and calculated as log2 fold-changes. Functional enrichment analyses of differentially expressed genes were undertaken using gene sets derived from the Biological Process Ontology from GSEA (http://software.broadinstitute.org/gsea/ msigdb/index.jsp).
Statistics. Data analyses were performed with Clampfit (Molecular Devices, Sunnyvale, CA), KaleidaGraph (Synergy Software, Reading, PA) and GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA). For statistical significance, experiments with two groups were analyzed using two-tailed Student's t tests. Experiments with more than two groups were subjected to one-way ANOVA, two-way ANOVA or two-way repeated measurea ANOVA (rmANOVA), followed by post hoc Bonferroni tests for multiple comparisons. Measurements were taken from distinct samples. No sample was excluded from the analysis. Sample sizes were based on power analyses and were similar to those reported in previous works 12, 43, 44 . We tested the normality and variance of data distribution between groups being statistically compared. Data in box plots are presented as: center line, median; box limits, upper and lower quartiles; whiskers, minimal and maximum values. Data in all other formats are presented as mean ± s.e.m. F values, degrees of freedom and P values for all ANOVAs (unless otherwise stated, they represent statistics of main interaction effects and post hoc comparisons), as well as t-values and degrees of freedom for t tests, are included in figure legends.
Accession codes. Accession codes have been deposited at GEO: GSE109328.
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Data exclusions
Describe any data exclusions.
No data was excluded in analysis.
Replication
Describe whether the experimental findings were reliably reproduced.
We listed the number of times we repeated the experiments in figure legends. The behavioral phenotypes reported here (by K. Ma) were independently replicated by 3 other lab members (Drs. M. Rapanelli, Z-J Wang, and L. Duffney).
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
Mice of different genotypes were randomly assigned to drug/saline groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
The investigator was blinded to the group allocation (with no prior knowledge about the genotypes and treatments) during the experiments.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
